PriceTargets.com logo

Stoke Therapeutics - STOK Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $31.00
  • Forecasted Upside: -0.16%
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 6 Buy Ratings
  • 2 Strong Buy Ratings
$31.05 As of 12/4/2025 05:00 PM ET
▲ +0.09 (0.29%)

This chart shows the closing price for STOK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Stoke Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for STOK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for STOK

Analyst Price Target is $31.00
▼ -0.16% Downside Potential
This price target is based on 10 analysts offering 12 month price targets for Stoke Therapeutics in the last 3 months. The average price target is $31.00, with a high forecast of $39.00 and a low forecast of $24.00. The average price target represents a -0.16% upside from the last price of $31.05.

This chart shows the closing price for STOK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 10 investment analysts is to buy stock in Stoke Therapeutics. This rating changed within the last month from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 1 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 1 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 2 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 2 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 2 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 2 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/1/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
11/19/2025Weiss RatingsReiterated RatingHold (C-) ➝ Hold (C-)
11/19/2025Chardan CapitalUpgradeStrong-Buy
11/13/2025Weiss RatingsReiterated RatingHold (C-) ➝ Hold (C-)
11/7/2025Weiss RatingsUpgradeSell (D+) ➝ Hold (C-)
11/5/2025Canaccord Genuity GroupBoost TargetBuy ➝ Buy$24.00 ➝ $28.00
11/5/2025WedbushBoost TargetOutperform ➝ Outperform$22.00 ➝ $32.00
11/5/2025BTIG ResearchReiterated RatingBuy ➝ Buy$39.00
11/3/2025JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$15.00 ➝ $25.00
10/13/2025BTIG ResearchBoost TargetBuy ➝ Buy$28.00 ➝ $39.00
10/10/2025Needham & Company LLCBoost TargetBuy ➝ Buy$22.00 ➝ $35.00
10/8/2025Weiss RatingsReiterated RatingSell (D+) ➝ Sell (D+)
9/27/2025Weiss RatingsReiterated RatingSell (D+) ➝ Sell (D+)
8/18/2025BTIG ResearchSet TargetBuy ➝ Buy$28.00
8/13/2025Chardan CapitalReiterated RatingBuy ➝ Buy$24.00
8/13/2025WedbushBoost TargetOutperform ➝ Outperform$16.00 ➝ $22.00
7/18/2025Jefferies Financial GroupInitiated CoverageBuy$30.00
7/1/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$22.00
5/14/2025Cantor FitzgeraldUpgradeStrong-Buy
5/14/2025HC WainwrightLower TargetBuy ➝ Buy$47.00 ➝ $35.00
4/9/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
3/19/2025HC WainwrightReiterated RatingBuy ➝ Buy$47.00 ➝ $47.00
3/19/2025Chardan CapitalReiterated RatingBuy ➝ Buy$24.00 ➝ $24.00
3/18/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
2/19/2025Chardan CapitalReiterated RatingBuy ➝ Buy$24.00 ➝ $24.00
2/18/2025HC WainwrightBoost TargetBuy ➝ Buy$35.00 ➝ $47.00
2/18/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
1/8/2025HC WainwrightReiterated RatingBuy ➝ Buy$35.00 ➝ $35.00
1/8/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
12/20/2024Chardan CapitalInitiated CoverageBuy$24.00
12/10/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight
11/6/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
11/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$35.00 ➝ $35.00
10/14/2024Leerink PartnersInitiated CoverageOutperform$18.00
10/11/2024Leerink PartnrsUpgradeStrong-Buy
9/11/2024HC WainwrightReiterated RatingBuy ➝ Buy$35.00 ➝ $35.00
8/8/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
7/11/2024WedbushReiterated RatingOutperform ➝ Outperform$17.00 ➝ $17.00
6/28/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
5/7/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$21.00 ➝ $20.00
5/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$35.00
5/6/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$22.00
4/11/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$22.00
4/4/2024Cantor FitzgeraldReiterated RatingOverweight
3/26/2024WedbushBoost TargetOutperform ➝ Outperform$13.00 ➝ $17.00
3/26/2024Needham & Company LLCBoost TargetBuy ➝ Buy$14.00 ➝ $22.00
3/26/2024HC WainwrightReiterated RatingBuy ➝ Buy$35.00
3/26/2024TD CowenUpgradeMarket Perform ➝ Outperform
3/26/2024JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$6.00 ➝ $13.00
3/26/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$18.00 ➝ $21.00
2/16/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$14.00
11/7/2023Needham & Company LLCLower TargetBuy ➝ Buy$25.00 ➝ $14.00
8/8/2023Cantor FitzgeraldLower TargetOverweight ➝ Overweight$18.00 ➝ $14.00
8/8/2023Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$23.00
8/8/2023HC WainwrightReiterated RatingBuy ➝ Buy$35.00
8/7/2023Needham & Company LLCReiterated RatingBuy$25.00
7/31/2023HC WainwrightReiterated RatingBuy ➝ Buy$35.00
7/25/2023TD CowenDowngradeOutperform ➝ Market Perform
5/23/2023Cantor FitzgeraldBoost Target$20.00 ➝ $25.00
5/1/2023Bank of AmericaUpgradeUnderperform ➝ Neutral$9.00 ➝ $12.00
4/26/2023Canaccord Genuity GroupInitiated CoverageBuy$24.00
3/16/2023Needham & Company LLCReiterated RatingBuy$25.00
3/7/2023Needham & Company LLCReiterated RatingBuy$25.00
3/7/2023HC WainwrightReiterated RatingBuy$35.00
3/7/2023Credit Suisse GroupLower TargetOutperform$32.00 ➝ $28.00
3/7/2023Cantor FitzgeraldReiterated RatingOverweight$20.00
3/7/2023WedbushLower TargetOutperform$33.00 ➝ $25.00
1/11/2023Credit Suisse GroupLower TargetOutperform$38.00 ➝ $32.00
1/6/2023Bank of AmericaDowngradeBuy ➝ Underperform$22.00 ➝ $9.00
12/5/2022HC WainwrightLower TargetBuy$70.00 ➝ $35.00
11/15/2022Cantor FitzgeraldLower Target$38.00 ➝ $20.00
11/15/2022Credit Suisse GroupLower TargetOutperform$50.00 ➝ $38.00
11/14/2022Needham & Company LLCLower TargetBuy$50.00 ➝ $25.00
10/24/2022Leerink PartnersUpgradeMarket Perform ➝ Outperform$30.00
8/15/2022Credit Suisse GroupLower Target$50.00
8/8/2022Needham & Company LLCLower TargetBuy$65.00 ➝ $50.00
5/26/2022Cantor FitzgeraldLower Target$68.00 ➝ $38.00
4/1/2022Cantor FitzgeraldReiterated RatingOverweight
3/16/2022Bank of AmericaLower TargetBuy$43.00 ➝ $40.00
1/31/2022Jefferies Financial GroupInitiated CoverageBuy$50.00
12/3/2021Bank of AmericaInitiated CoverageBuy$43.00
11/22/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$41.00
11/9/2021Cantor FitzgeraldReiterated RatingOverweight
9/22/2021HC WainwrightReiterated RatingBuy$70.00
8/17/2021Cantor FitzgeraldLower TargetOverweight$76.00 ➝ $68.00
5/18/2021UBS GroupInitiated CoverageNeutral$35.00
5/10/2021WedbushUpgradeNeutral ➝ Outperform
3/10/2021Credit Suisse GroupBoost TargetOutperform$49.00 ➝ $58.00
2/10/2021WedbushDowngradeOutperform ➝ Neutral
1/14/2021Needham & Company LLCBoost TargetPositive ➝ Buy$56.00 ➝ $65.00
12/15/2020HC WainwrightReiterated RatingBuy$70.00
12/11/2020Needham & Company LLCBoost TargetBuy$48.00 ➝ $56.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

0.88 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 18 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 11 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 7 very positive mentions
  • 18 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 25 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 17 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 14 very positive mentions
  • 25 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 18 very positive mentions
  • 23 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 18 very positive mentions
  • 23 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Stoke Therapeutics logo
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Read More

Today's Range

Now: $31.05
Low: $30.10
High: $31.54

50 Day Range

MA: $28.90
Low: $22.37
High: $35.60

52 Week Range

Now: $31.05
Low: $5.35
High: $38.69

Volume

659,414 shs

Average Volume

951,880 shs

Market Capitalization

$1.77 billion

P/E Ratio

46.34

Dividend Yield

N/A

Beta

1.14

Frequently Asked Questions

What sell-side analysts currently cover shares of Stoke Therapeutics?

The following Wall Street research analysts have issued research reports on Stoke Therapeutics in the last twelve months: BTIG Research, Canaccord Genuity Group Inc., Cantor Fitzgerald, Chardan Capital, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Needham & Company LLC, Wedbush, and Weiss Ratings.
View the latest analyst ratings for STOK.

What is the current price target for Stoke Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Stoke Therapeutics in the last year. Their average twelve-month price target is $31.00, suggesting a possible downside of 0.2%. BTIG Research has the highest price target set, predicting STOK will reach $39.00 in the next twelve months. Chardan Capital has the lowest price target set, forecasting a price of $24.00 for Stoke Therapeutics in the next year.
View the latest price targets for STOK.

What is the current consensus analyst rating for Stoke Therapeutics?

Stoke Therapeutics currently has 2 hold ratings, 6 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe STOK will outperform the market and that investors should add to their positions of Stoke Therapeutics.
View the latest ratings for STOK.

What other companies compete with Stoke Therapeutics?

Other companies that are similar to Stoke Therapeutics include Rhythm Pharmaceuticals, Cidara Therapeutics, Vaxcyte, PTC Therapeutics and Krystal Biotech. Learn More about companies similar to Stoke Therapeutics.

How do I contact Stoke Therapeutics' investor relations team?

Stoke Therapeutics' physical mailing address is 45 WIGGINS AVENUE, BEDFORD MA, 01730. The company's listed phone number is (781) 430-8200 and its investor relations email address is [email protected]. The official website for Stoke Therapeutics is www.stoketherapeutics.com. Learn More about contacing Stoke Therapeutics investor relations.